NCT07426094 PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer
| NCT ID | NCT07426094 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Affidea Nu-med Center of Oncological DIagnostics and Therapy |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2026-03-19 |
| Primary Completion | 2033-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 600 participants in total. It began in 2026-03-19 with a primary completion date of 2033-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
PRO-BOOST-N is a prospective, multicenter, randomized phase II/III clinical trial for patients with prostate cancer and pelvic lymph node involvement (cN1M0) confirmed by PSMA PET/CT, without distant metastatic disease. Patients with PSMA PET-staged node-positive prostate cancer are potentially curable, but remain at substantial risk of distant progression despite contemporary treatment with radiotherapy, long-term androgen deprivation therapy, and, when appropriate, androgen receptor pathway inhibitors. The optimal way to intensify radiotherapy to the prostate and PSMA PET-positive pelvic lymph nodes remains uncertain in the era of modern molecular imaging. All participants receive a standardized ultrahypofractionated whole-pelvis radiotherapy backbone delivered in five fractions, combined with long-term systemic therapy according to contemporary clinical practice. The study uses a 2 x 2 factorial randomized design to evaluate two treatment questions. The primary comparison evaluates whether prostate dose escalation improves metastasis-free survival compared with no additional prostate boost. Patients assigned to prostate boost receive one of three protocol-defined boost techniques: high-dose-rate brachytherapy, low-dose-rate brachytherapy, or single-fraction SBRT. If more than one prostate boost technique is available at the treating center and technically suitable for the patient, the boost technique is assigned by embedded subrandomization. The key secondary, hierarchically tested comparison evaluates nodal dose escalation by comparing two predefined dose levels to PSMA PET-positive pelvic lymph nodes. Organ-at-risk-driven nodal dose de-escalation is permitted within the higher-dose arm when required for patient safety and protocol compliance. The primary endpoint is metastasis-free survival (MFS) . Secondary endpoints include overall survival (OS), radiographic progression-free survival (rPFS), intraprostatic and regional nodal control, time to castration-resistant prostate cancer, time to next systemic therapy, treatment-related adverse events graded according to CTCAE version 6.0, and patient-reported quality of life, including urinary, bowel, sexual, and global health domains. PRO-BOOST-N aims to determine the optimal radiotherapy intensification strategy for patients with PSMA PET-staged node-positive prostate cancer by prospectively evaluating prostate-directed and nodal-directed dose escalation within a modern, standardized radiotherapy platform.
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate. * Prostate cancer with clinically positive pelvic lymph nodes (cN1) without evidence of distant metastatic disease. * Pelvic lymph node involvement limited to regional pelvic lymph nodes (obturator, internal iliac, external iliac, presacral), as assessed by conventional imaging and/or PSMA PET/CT. * No evidence of distant metastatic disease (M0), including absence of non-regional nodal, bone, or visceral metastases. * Candidate for definitive radiotherapy to the prostate and elective pelvic lymph nodes. * Planned treatment with androgen deprivation therapy with or without androgen receptor pathway inhibitors according to protocol. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Adequate organ function allowing delivery of protocol-defined radiotherapy and systemic therapy. * Age ≥18 years. * Ability to understand and willingness to sign a written informed consent. Exclusion Criteria: * Evidence of distant metastatic disease (M1), including non-regional lymph node, bone, or visceral metastases. * Prior definitive local therapy for prostate cancer, including radical prostatectomy, whole-gland radiotherapy, or brachytherapy. * Prior pelvic radiotherapy for any indication that would overlap planned treatment fields. * Prior systemic therapy for prostate cancer other than protocol-allowed neoadjuvant androgen deprivation therapy. * History of castration-resistant prostate cancer. * Concurrent malignancy requiring active treatment, except non-melanoma skin cancer or other malignancies with negligible risk of interference with study outcomes. * Severe uncontrolled comorbidities that would preclude safe delivery of radiotherapy or systemic therapy. * Any condition that, in the opinion of the investigator, would interfere with patient safety or compliance with the study protocol.
Contact & Investigator
Mateusz Bilski, MD, PhD
PRINCIPAL INVESTIGATOR
Affidea Nu-med Center of Oncological DIagnostics and Therapy
Frequently Asked Questions
Who can join the NCT07426094 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07426094 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07426094 currently recruiting?
Yes, NCT07426094 is actively recruiting participants. Contact the research team at bilskimat@gmail.com for enrollment information.
Where is the NCT07426094 trial being conducted?
This trial is being conducted at Zamość, Poland.
Who is sponsoring the NCT07426094 clinical trial?
NCT07426094 is sponsored by Affidea Nu-med Center of Oncological DIagnostics and Therapy. The principal investigator is Mateusz Bilski, MD, PhD at Affidea Nu-med Center of Oncological DIagnostics and Therapy. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.